PortalPublikationenA therapeutic exploratory study to determine the efficacy an...

A therapeutic exploratory study to determine the efficacy and safety of calcineurin-inhibitor-free de-novo immunosuppression after liver transplantation: CILT.

Standard

A therapeutic exploratory study to determine the efficacy and safety of calcineurin-inhibitor-free de-novo immunosuppression after liver transplantation: CILT. / Goralczyk, Armin D; Schnitzbauer, Andreas; Tsui, Tung Yu; Ramadori, Giuliano; Lorf, Thomas; Obed, Aiman.

in: BMC SURG, Jahrgang 10, 2010, S. 15.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Goralczyk, AD, Schnitzbauer, A, Tsui, TY, Ramadori, G, Lorf, T & Obed, A 2010, 'A therapeutic exploratory study to determine the efficacy and safety of calcineurin-inhibitor-free de-novo immunosuppression after liver transplantation: CILT.', BMC SURG, Jg. 10, S. 15. https://doi.org/10.1186/1471-2482-10-15

APA

Goralczyk, A. D., Schnitzbauer, A., Tsui, T. Y., Ramadori, G., Lorf, T., & Obed, A. (2010). A therapeutic exploratory study to determine the efficacy and safety of calcineurin-inhibitor-free de-novo immunosuppression after liver transplantation: CILT. BMC SURG, 10, 15. https://doi.org/10.1186/1471-2482-10-15

Vancouver

Goralczyk AD, Schnitzbauer A, Tsui TY, Ramadori G, Lorf T, Obed A. A therapeutic exploratory study to determine the efficacy and safety of calcineurin-inhibitor-free de-novo immunosuppression after liver transplantation: CILT. BMC SURG. 2010;10:15. https://doi.org/10.1186/1471-2482-10-15

Bibtex

@article{568676934e7049c8bc45673fbd07750a,
title = "A therapeutic exploratory study to determine the efficacy and safety of calcineurin-inhibitor-free de-novo immunosuppression after liver transplantation: CILT.",
abstract = "Immunosuppression with calcineurin inhibitors (CNI) increases the risk of renal dysfunction after orthotopic liver transplantation (OLT). Controlled trials have shown improvement of renal function in patients that received delayed and/or reduced-dose CNI after OLT. Delaying immunosuppression with CNI in combination with induction therapy does not increase the risk of acute rejection but reduces the incidence of acute renal dysfunction. Based on this clinical data this study protocol was designed to assess the efficacy and safety of calcineurin-inhibitor-free de-novo immunosuppression after liver transplantation.",
author = "Goralczyk, {Armin D} and Andreas Schnitzbauer and Tsui, {Tung Yu} and Giuliano Ramadori and Thomas Lorf and Aiman Obed",
year = "2010",
doi = "10.1186/1471-2482-10-15",
language = "Deutsch",
volume = "10",
pages = "15",
journal = "BMC SURG",
issn = "1471-2482",
publisher = "BioMed Central Ltd.",

}

RIS

TY - JOUR

T1 - A therapeutic exploratory study to determine the efficacy and safety of calcineurin-inhibitor-free de-novo immunosuppression after liver transplantation: CILT.

AU - Goralczyk, Armin D

AU - Schnitzbauer, Andreas

AU - Tsui, Tung Yu

AU - Ramadori, Giuliano

AU - Lorf, Thomas

AU - Obed, Aiman

PY - 2010

Y1 - 2010

N2 - Immunosuppression with calcineurin inhibitors (CNI) increases the risk of renal dysfunction after orthotopic liver transplantation (OLT). Controlled trials have shown improvement of renal function in patients that received delayed and/or reduced-dose CNI after OLT. Delaying immunosuppression with CNI in combination with induction therapy does not increase the risk of acute rejection but reduces the incidence of acute renal dysfunction. Based on this clinical data this study protocol was designed to assess the efficacy and safety of calcineurin-inhibitor-free de-novo immunosuppression after liver transplantation.

AB - Immunosuppression with calcineurin inhibitors (CNI) increases the risk of renal dysfunction after orthotopic liver transplantation (OLT). Controlled trials have shown improvement of renal function in patients that received delayed and/or reduced-dose CNI after OLT. Delaying immunosuppression with CNI in combination with induction therapy does not increase the risk of acute rejection but reduces the incidence of acute renal dysfunction. Based on this clinical data this study protocol was designed to assess the efficacy and safety of calcineurin-inhibitor-free de-novo immunosuppression after liver transplantation.

U2 - 10.1186/1471-2482-10-15

DO - 10.1186/1471-2482-10-15

M3 - SCORING: Zeitschriftenaufsatz

VL - 10

SP - 15

JO - BMC SURG

JF - BMC SURG

SN - 1471-2482

ER -